Study of JYB1904 for chronic hives
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new medicine, JYB1904, for people with chronic hives (itching and welts) that haven't been controlled by standard allergy pills. It aims to see if JYB1904 can reduce itching and hives better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had chronic hives for at least 3 months.
- Your hives and itching have not been well controlled with regular allergy pills like Zyrtec or Claritin.
- You have had itching and hives for at least 6 weeks before starting the study.
- Your hives and itching scores are high enough based on a 7-day diary before you start treatment.
- You do not have other skin conditions that cause itching, like eczema or psoriasis, or hives with a known trigger like cold or pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injectable medicine (JYB1904) to see if it can reduce itching and hives better than standard antihistamines alone. If you have chronic hives with no clear cause and still get symptoms despite taking antihistamines, this study may be an option for you.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
This trial tests a treatment plan using remibrutinib (a pill) and omalizumab (a biologic shot) for adults with chronic spontaneous urticaria (chronic hives) that are not well controlled by antihistamines. The goal is to see if this combination can reduce itching and hives better than current options.
This study tests a new medication called HRS-3095 to see if it can help people whose chronic hives (itchy welts) do not get better with standard allergy pills. It aims to reduce itching and wheals and improve quality of life.
This study tests an experimental capsule (HS-10561) to see if it is safe and works for people with chronic spontaneous urticaria, which causes hives and itching without a clear trigger. If you have had hives for at least 6 months, you might be able to join.
This Phase 4 study looks at whether extending the time between omalizumab injections can still control chronic spontaneous hives (CSU). It may help some people need fewer injections while keeping symptoms under control.
Hear when a new Chronic Spontaneous Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.